For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Kokando Told to Suspend Business for Up to 36 Days over Decades-Long Violations
November 14, 2022
- Online Submissions for Generic Approval to Start from January
November 14, 2022
- Pro-Industry Lawmakers, Govt Remain Widely Divided over Off-Year Plan
November 11, 2022
- MHLW Reserves Extra Budget to Build Gene Therapy Support Consortium
November 11, 2022
- Drug Price Negotiations by Consultants Might Violate Distribution Guidelines: Official
November 11, 2022
- Zero Coefficient Rule Hits All 10 Premium-Granted Drugs Priced by Cost Formula in FY2022
November 11, 2022
- Japan to Roll Out Moderna’s BA.4/5 Booster from Nov. 28
November 11, 2022
- Expert Panel Discussion Summary Reported to Chuikyo; Payer Rep Sees No Need for Inflation Response in Off Year
November 10, 2022
- Polivy Likely to Escape CEA-Based Price Tweaks
November 10, 2022
- MHLW Earmarks 55 Billion Yen for Domestic Antibiotic API Production: Extra Budget
November 10, 2022
- Extra Budget to Cover Enough COVID Vaccine Purchases until Next Winter
November 10, 2022
- METI Looks to Bolster Pharma Startup Ecosystem with 6-Fold Hike in Extra Budget
November 10, 2022
- Skyrizi Auto-Doser Peak Sales Put at 30-Plus Billion Yen, Mounjaro Not on Roster: November Listing
November 10, 2022
- Industry Reiterates Call for Careful Discussions on Off-Year Revision: LDP Confab
November 10, 2022
- 9-Valent HPV Vaccine Program to Start in April, Panel Seeks Early Approval of 2-Dose Regimen
November 9, 2022
- Bill to Amend Infectious Disease Act Clears Lower House
November 9, 2022
- Pharma, Payers Nudge MHLW to Speed Up Data Supply from NDB
November 9, 2022
- MOF Panel Member Calls for Drug Price Cuts to Unleash Innovation, Ease Household Burdens
November 8, 2022
- Japan Panel Recognizes 6 More Deaths Possibly Linked to COVID Vaccines
November 8, 2022
- MOF Proposes Transition to Normal Framework for COVID Vaccines, Therapeutics
November 8, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…